Showing results (2011-2020 of 2,061) with videos related to

Sort By:
Pageof 207
Diabetes & Metabolism Journal|March 7, 2022
A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes MellitusBo-Yeon Kim, Hyuk-Sang Kwon, Suk Kyeong Kim, et al.
Cell Death & Disease|July 31, 2019
Cep131 overexpression promotes centrosome amplification and colon cancer progression by regulating Plk4 stabilityDong Hyun Kim, Jong Seog Ahn, Ho Jin Han, et al.
Radiation Oncology (London, England)|July 3, 2015
Evaluation of variability in target volume delineation for newly diagnosed glioblastoma: a multi-institutional study from the Korean Radiation Oncology GroupChan Woo Wee, Wonmo Sung, Hyun-Cheol Kang, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 6, 2016
Long-term clinical study and multiscale analysis of in vivo biodegradation mechanism of Mg alloyJee-Wook Lee, Hyung-Seop Han, Kyeong-Jin Han, et al.
Signal Transduction and Targeted Therapy|April 28, 2022
Broadly neutralizing antibodies against Omicron-included SARS-CoV-2 variants induced by vaccinationXiangyang Chi, Yingying Guo, Guanying Zhang, et al.
Experimental & Molecular Medicine|February 14, 2019
Mechanism of the natural product moracin-O derived MO-460 and its targeting protein hnRNPA2B1 on HIF-1α inhibitionNak-Kyun Soung, Hye-Min Kim, Yukihiro Asami, et al.
Nature Medicine|December 4, 2012
Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a mitokineKook Hwan Kim, Yeon Taek Jeong, Hyunhee Oh, et al.
JACC. Basic to Translational Science|January 23, 2023
Novel GSK-3β Inhibitor Neopetroside A Protects Against Murine Myocardial Ischemia/Reperfusion InjuryHyoung Kyu Kim, Min Kim, Jubert C Marquez, et al.
Frontiers in Immunology|March 22, 2024
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine productionKwangmin Na, Seul Lee, Dong Kwon Kim, et al.
Anticancer Research|September 30, 2024
PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLCInsu Kim, Sun Ha Choi, Shin Yup Lee, et al.
Pageof 207